ESPR - Public offerings

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a public offering price of $2.50 per share. In addition, Esperion has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds to Esperion from the offering, before deducting underwrit

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced that it has commenced an underwritten public offering of shares of its common stock. Esperion also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. All of the shares of common stock in the proposed offering are to be sold by Es

WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. "We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "As a highly accomplished drug development executive and physician, Noah's deep expertise will significantly help our efforts to establish YCANTH® as the new standard of care for the treatment of mo

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – – New Facility Represents $150 Million Strategic Investment Led by Healthcare Specialist Athyrium Capital Management and Joined by HealthCare Royalty – ANN ARBOR, Mich., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has closed on a series of financing transactions that will support the Company's repayment of a portion of its existing $265 million convertible debt facility. The transactions included a $150 million senior secured term loan facility (the "Loan") led by funds managed by Athyr

– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non-Statins to Prevent Heart Attacks and Reduce Cardiovascular Risk in Primary and Secondary Prevention Patients – – Received Positive Opinion from the Committee for Medical Products for Human Use (CHMP); European Commission Decisio

ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. ("Esperion", "we", "us" or "our") (NASDAQ:ESPR) announced today the closing of its previously announced underwritten public offering of 65,205,000 shares of its common stock, including 8,505,000 shares of its common stock pursuant to the underwriters' exercise in full of their option to purchase additional shares of common stock, at the public offering price of $1.50 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Esperion, are approximately $97.8 million. Jefferies LLC acted as sole book-running manager for the off

ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. ("Esperion", "we", "us" or "our") (NASDAQ:ESPR) announced today the pricing of its previously announced underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Esperion. In addition, Esperion granted the underwriters a 30-day option to purchase up to an additional 8,505,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts

ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. ("Esperion", "we", "us" or "our") (NASDAQ:ESPR) announced today that it has commenced an underwritten public offering of shares of its common stock. In connection with this offering, Esperion expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares to be sold in the proposed offering of common stock will be sold by Esperion. The offering of common stock is subject to market and other conditions and there can be no assurance as to whether or when the offering may b

ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) ("Esperion" or the "Company") today announced the closing of its previously announced registered direct offering of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock priced at-the-market under Nasdaq rules. Each share of common stock (or common stock equivalent in lieu thereof) was sold together with one short-term warrant to purchase one share of common stock at an effective combined purchase price of $1.675. The short-term warrants are immediately exercisable for a period o

ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) ("Esperion" or the "Company"), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock (or common stock equivalent in lieu thereof) is being sold together with one short-term warrant to purchase one share of common stock at a combined purchase p

– Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December – – Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 to $12.5 Million – – Company Reiterates Full-Year 2022 Operating Expense Guidance of $220 to $240 Million – ANN ARBOR, Mich., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced preliminary, unaudited fourth-quarter 2021 financial results and reiterated full-year 2022 operating expense guidance. "2021 was a transitional year for Esperion, as we ushered in a new leadership team, stabilized prescription demand with innovative s

ANN ARBOR, Mich., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) ("Esperion" or the "Company"), today announced the closing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and accompanying warrants to purchase an aggregate of up to 32,142,858 shares of common stock for gross proceeds of approximately $225 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company granted the underwriter a 30-day option to purchase up to an additional 4,821,428 shares of its common stock and/or additional warrants to purchase up to 4,821,428 shares of its common stock, which the underwrit

ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) ("Esperion" or the "Company"), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of 32,142,858 shares of common stock. Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock at a combined public offering price of $7.00 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The short-term warrants have an exercise price of $9.00 per share, are exercisable immediately, and will expire

ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) ("Esperion" or the "Company"), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in an underwritten public offering. The Company expects to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities to be sold in the offering are to be offered by Esperion. H.C. Wainwright &